ETON
NASDAQEton Pharmaceuticals Inc.
News · 26 weeks58+150%
2026-03-012026-08-23
Mix3590d
- Insider21(60%)
- SEC Filings9(26%)
- Other2(6%)
- Earnings2(6%)
- Analyst1(3%)
Latest news
25 items- INSIDERChief Business Officer Krempa David sold $1,626,750 worth of shares (25,000 units at $65.07) and exercised 25,000 shares at a strike of $7.31 (SEC Form 4)4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
- INSIDERPresident & CEO Brynjelsen Sean sold $6,087,773 worth of shares (100,000 units at $60.88), decreasing direct ownership by 9% to 961,194 units (SEC Form 4)4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
- SECAmendment: SEC Form 144/A filed by Eton Pharmaceuticals Inc.144/A - Eton Pharmaceuticals, Inc. (0001710340) (Subject)
- SECSEC Form 144 filed by Eton Pharmaceuticals Inc.144 - Eton Pharmaceuticals, Inc. (0001710340) (Subject)
- SECSEC Form 10-Q filed by Eton Pharmaceuticals Inc.10-Q - Eton Pharmaceuticals, Inc. (0001710340) (Filer)
- SECEton Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Eton Pharmaceuticals, Inc. (0001710340) (Filer)
- PREton Pharmaceuticals Reports Second Quarter 2026 Financial ResultsRecord revenue, with Q2 2026 product sales of $37.6 million, representing 99% growth over Q2 2025Q2 2026 fully diluted GAAP EPS of $0.35, non-GAAP fully diluted EPS of $0.43; EBITDA of $14.1 million, Adjusted EBITDA of $16.2 millionRaising full year revenue guidance, with 2026 revenue now expected to exceed $145 million, up from previous guidance of more than $120 millionRelaunched HEMANGEOL® May 1st, patient conversion completed ahead of scheduleAcquired late-stage product candidate ASN-001, expanding the Company’s infantile hemangioma franchise, and providing a potential high-value 2027 NDA submissionSubmitted Prior Approval Supplement to the FDA to expand indication of KHINDIVI®, allowing
- INSIDERNew insider Radosavljevic Danka claimed ownership of 22,473 shares (SEC Form 3)3 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
- SECEton Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits8-K - Eton Pharmaceuticals, Inc. (0001710340) (Filer)
- PREton Pharmaceuticals Expands Infantile Hemangioma Franchise with Acquisition of U.S. Rights to Late-Stage Product Candidate ASN-001ASN-001 targets the substantially larger population of moderate infantile hemangiomas currently treated off-label with topical timololComplementary product to HEMANGEOL® (propranolol hydrochloride) oral solution, positioning Eton, if approved, to treat full spectrum of infantile hemangioma patientsASN-001 Phase II/III trial results showed week 24 elimination or near-elimination rates of 56% (BID) and 42% (TID) compared with 15% for placeboAnticipate NDA submission in 2H 2027 for potential approval and launch in 2028Estimated 20,000 to 30,000 patients annually could be candidates for ASN-001, pathway to potentially be the largest revenue generating product in Eton’s portfolioLeverages Eton’s
- INSIDERSEC Form 4 filed by Director Casamento Charles J4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
- INSIDERSEC Form 4 filed by Chief Financial Officer Matthews Judith M.4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
- INSIDERSEC Form 4 filed by Chief Commercial Officer Erdogan-Trinkaus Ipek4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
- INSIDERSEC Form 4 filed by President & CEO Brynjelsen Sean4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
- INSIDERSEC Form 4 filed by Chief Business Officer Krempa David4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
- INSIDERSEC Form 4 filed by Director Maier Paul V4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
- INSIDERSEC Form 4 filed by Director Riedel Norbert G4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
- INSIDERSEC Form 4 filed by Director Adams Jennifer Mckie4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
- SECEton Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update8-K - Eton Pharmaceuticals, Inc. (0001710340) (Filer)
- PREton Pharmaceuticals to Report Second Quarter 2026 Financial Results on Thursday, August 13, 2026DEER PARK, Ill., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or the "Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report second quarter 2026 financial results on Thursday, August 13, 2026. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET (3:30 p.m. CT). Participant Call Link: Click Here Webcast: Click Here In addition to taking live questions from participants on the conference call, management will be answering emailed questions from investors. Investors can email questions to: investorrelatio
- SECEton Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Eton Pharmaceuticals, Inc. (0001710340) (Filer)
- PREton Pharmaceuticals Announces Submission of Prior Approval Supplement to Expand Indication of KHINDIVI® (hydrocortisone) Oral SolutionFDA submission seeks to bring KHINDIVI to larger pediatric patient population within the adrenal insufficiency marketNew formulation successfully demonstrated bioequivalence to ALKINDI SPRINKLE®Submission allows for a potential first half 2027 approval of the expanded indication DEER PARK, Ill., July 29, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or "the Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that the Company’s new formulation of KHINDIVI (hydrocortisone) oral solution successfully showed bioequivalence to ALKINDI SPRINKLE (hydrocortisone) oral granules, the FDA-
- INSIDERAmendment: Large owner Opaleye Management Inc. sold $1,063,033 worth of shares (28,315 units at $37.54) (SEC Form 4)4/A - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
- ANALYSTCanaccord Genuity initiated coverage on Eton Pharmaceuticals with a new price targetCanaccord Genuity initiated coverage of Eton Pharmaceuticals with a rating of Buy and set a new price target of $60.00
- INSIDERLarge owner Opaleye Management Inc. sold $1,063,033 worth of shares (28,315 units at $37.54) (SEC Form 4)4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
ETON FAQ
7 questionsWhat does Eton Pharmaceuticals Inc. do?
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; and Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis. It also develops ET-105, a lamotrigine for oral suspension...Where does ETON stock trade?
Eton Pharmaceuticals Inc. (ETON) is listed on NASDAQ.What sector and industry is ETON in?
Eton Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Eton Pharmaceuticals Inc. go public?
Eton Pharmaceuticals Inc. (ETON) completed its IPO in 2018.What are analysts saying about ETON?
Eton Pharmaceuticals Inc. has had 7 recent analyst actions on file. The most recent action was from Canaccord Genuity: Buy on 2026-07-17. Recent price targets range from $800.00 to $3300.00.What companies are similar to ETON?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare ETON side-by-side with any of them on Quantisnow.How can I track ETON on Quantisnow?
Quantisnow aggregates Eton Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ETON to receive live email and push alerts on every new disclosure.